vs
BlueLinx Holdings Inc.（BXC）与Revvity（RVTY）财务数据对比。点击上方公司名可切换其他公司
Revvity的季度营收约是BlueLinx Holdings Inc.的1.0倍（$772.1M vs $748.9M），Revvity净利率更高（12.7% vs 0.2%，领先12.5%），Revvity同比增速更快（5.9% vs 0.2%），Revvity自由现金流更多（$161.8M vs $52.7M），过去两年Revvity的营收复合增速更高（9.0% vs 2.5%）
BlueLinx Holdings Inc.是美国经营建材与工业产品的批发分销商，总部位于佐治亚州亚特兰大，目前由Shyam Reddy担任公司总裁兼首席执行官，在美国本土相关分销领域开展业务
Revvity是一家美国生命科学与诊断领域企业，主要服务制药、生物技术行业客户，重点围绕细胞治疗、基因治疗等前沿技术领域提供相关产品与解决方案，其前身为业务布局多元的老牌企业珀金埃尔默。
BXC vs RVTY — 直观对比
营收规模更大
RVTY
是对方的1.0倍
$748.9M
营收增速更快
RVTY
高出5.6%
0.2%
净利率更高
RVTY
高出12.5%
0.2%
自由现金流更多
RVTY
多$109.1M
$52.7M
两年增速更快
RVTY
近两年复合增速
2.5%
损益表 — Q3 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $748.9M | $772.1M |
| 净利润 | $1.7M | $98.4M |
| 毛利率 | 14.4% | — |
| 营业利润率 | 1.3% | 14.5% |
| 净利率 | 0.2% | 12.7% |
| 营收同比 | 0.2% | 5.9% |
| 净利润同比 | -89.7% | 3.9% |
| 每股收益（稀释后） | $0.20 | $0.86 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BXCRVTY
| Q4 25 | — | $772.1M | ||
| Q3 25 | $748.9M | $698.9M | ||
| Q2 25 | $780.1M | $720.3M | ||
| Q1 25 | $709.2M | $664.8M | ||
| Q4 24 | $710.6M | $729.4M | ||
| Q3 24 | $747.3M | $684.0M | ||
| Q2 24 | $768.4M | $691.7M | ||
| Q1 24 | $726.2M | $649.9M |
净利润BXCRVTY
| Q4 25 | — | $98.4M | ||
| Q3 25 | $1.7M | $46.7M | ||
| Q2 25 | $4.3M | $53.9M | ||
| Q1 25 | $2.8M | $42.2M | ||
| Q4 24 | — | $94.6M | ||
| Q3 24 | $16.0M | $94.4M | ||
| Q2 24 | $14.3M | $55.4M | ||
| Q1 24 | $17.5M | $26.0M |
毛利率BXCRVTY
| Q4 25 | — | — | ||
| Q3 25 | 14.4% | 53.6% | ||
| Q2 25 | 15.3% | 54.5% | ||
| Q1 25 | 15.7% | 56.5% | ||
| Q4 24 | 15.9% | — | ||
| Q3 24 | 16.8% | 56.3% | ||
| Q2 24 | 15.9% | 55.7% | ||
| Q1 24 | 17.6% | 54.6% |
营业利润率BXCRVTY
| Q4 25 | — | 14.5% | ||
| Q3 25 | 1.3% | 11.7% | ||
| Q2 25 | 1.9% | 12.6% | ||
| Q1 25 | 1.5% | 10.9% | ||
| Q4 24 | 1.7% | 16.3% | ||
| Q3 24 | 3.2% | 14.3% | ||
| Q2 24 | 3.1% | 12.4% | ||
| Q1 24 | 3.8% | 6.8% |
净利率BXCRVTY
| Q4 25 | — | 12.7% | ||
| Q3 25 | 0.2% | 6.7% | ||
| Q2 25 | 0.6% | 7.5% | ||
| Q1 25 | 0.4% | 6.4% | ||
| Q4 24 | — | 13.0% | ||
| Q3 24 | 2.1% | 13.8% | ||
| Q2 24 | 1.9% | 8.0% | ||
| Q1 24 | 2.4% | 4.0% |
每股收益（稀释后）BXCRVTY
| Q4 25 | — | $0.86 | ||
| Q3 25 | $0.20 | $0.40 | ||
| Q2 25 | $0.54 | $0.46 | ||
| Q1 25 | $0.33 | $0.35 | ||
| Q4 24 | $0.67 | $0.77 | ||
| Q3 24 | $1.87 | $0.77 | ||
| Q2 24 | $1.65 | $0.45 | ||
| Q1 24 | $2.00 | $0.21 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $429.4M | $919.9M |
| 总债务越低越好 | $598.5M | — |
| 股东权益账面价值 | $623.0M | $7.3B |
| 总资产 | $1.6B | $12.2B |
| 负债/权益比越低杠杆越低 | 0.96× | — |
8季度趋势，按日历期对齐
现金及短期投资BXCRVTY
| Q4 25 | — | $919.9M | ||
| Q3 25 | $429.4M | $931.4M | ||
| Q2 25 | $386.8M | $991.8M | ||
| Q1 25 | $449.0M | $1.1B | ||
| Q4 24 | $505.6M | $1.2B | ||
| Q3 24 | $526.3M | $1.2B | ||
| Q2 24 | $491.4M | $2.0B | ||
| Q1 24 | $481.3M | $1.7B |
总债务BXCRVTY
| Q4 25 | — | — | ||
| Q3 25 | $598.5M | — | ||
| Q2 25 | $596.4M | — | ||
| Q1 25 | $596.6M | — | ||
| Q4 24 | $575.1M | — | ||
| Q3 24 | $576.0M | — | ||
| Q2 24 | $574.6M | — | ||
| Q1 24 | $574.0M | — |
股东权益BXCRVTY
| Q4 25 | — | $7.3B | ||
| Q3 25 | $623.0M | $7.4B | ||
| Q2 25 | $621.3M | $7.6B | ||
| Q1 25 | $636.1M | $7.6B | ||
| Q4 24 | $646.4M | $7.7B | ||
| Q3 24 | $655.6M | $7.9B | ||
| Q2 24 | $652.3M | $7.9B | ||
| Q1 24 | $653.2M | $7.8B |
总资产BXCRVTY
| Q4 25 | — | $12.2B | ||
| Q3 25 | $1.6B | $12.1B | ||
| Q2 25 | $1.6B | $12.4B | ||
| Q1 25 | $1.6B | $12.4B | ||
| Q4 24 | $1.6B | $12.4B | ||
| Q3 24 | $1.6B | $12.8B | ||
| Q2 24 | $1.6B | $13.4B | ||
| Q1 24 | $1.6B | $13.4B |
负债/权益比BXCRVTY
| Q4 25 | — | — | ||
| Q3 25 | 0.96× | — | ||
| Q2 25 | 0.96× | — | ||
| Q1 25 | 0.94× | — | ||
| Q4 24 | 0.89× | — | ||
| Q3 24 | 0.88× | — | ||
| Q2 24 | 0.88× | — | ||
| Q1 24 | 0.88× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $58.6M | $182.0M |
| 自由现金流经营现金流 - 资本支出 | $52.7M | $161.8M |
| 自由现金流率自由现金流/营收 | 7.0% | 21.0% |
| 资本支出强度资本支出/营收 | 0.8% | 2.6% |
| 现金转化率经营现金流/净利润 | 35.42× | 1.85× |
| 过去12个月自由现金流最近4个季度 | $-25.1M | $509.4M |
8季度趋势，按日历期对齐
经营现金流BXCRVTY
| Q4 25 | — | $182.0M | ||
| Q3 25 | $58.6M | $138.5M | ||
| Q2 25 | $-26.8M | $134.3M | ||
| Q1 25 | $-33.9M | $128.2M | ||
| Q4 24 | $18.7M | $174.2M | ||
| Q3 24 | $61.8M | $147.9M | ||
| Q2 24 | $35.8M | $158.6M | ||
| Q1 24 | $-31.1M | $147.6M |
自由现金流BXCRVTY
| Q4 25 | — | $161.8M | ||
| Q3 25 | $52.7M | $120.0M | ||
| Q2 25 | $-36.4M | $115.5M | ||
| Q1 25 | $-39.8M | $112.2M | ||
| Q4 24 | $-1.5M | $149.8M | ||
| Q3 24 | $53.8M | $125.6M | ||
| Q2 24 | $29.3M | $136.6M | ||
| Q1 24 | $-36.6M | $129.7M |
自由现金流率BXCRVTY
| Q4 25 | — | 21.0% | ||
| Q3 25 | 7.0% | 17.2% | ||
| Q2 25 | -4.7% | 16.0% | ||
| Q1 25 | -5.6% | 16.9% | ||
| Q4 24 | -0.2% | 20.5% | ||
| Q3 24 | 7.2% | 18.4% | ||
| Q2 24 | 3.8% | 19.7% | ||
| Q1 24 | -5.0% | 20.0% |
资本支出强度BXCRVTY
| Q4 25 | — | 2.6% | ||
| Q3 25 | 0.8% | 2.6% | ||
| Q2 25 | 1.2% | 2.6% | ||
| Q1 25 | 0.8% | 2.4% | ||
| Q4 24 | 2.9% | 3.4% | ||
| Q3 24 | 1.1% | 3.3% | ||
| Q2 24 | 0.8% | 3.2% | ||
| Q1 24 | 0.8% | 2.7% |
现金转化率BXCRVTY
| Q4 25 | — | 1.85× | ||
| Q3 25 | 35.42× | 2.97× | ||
| Q2 25 | -6.21× | 2.49× | ||
| Q1 25 | -12.09× | 3.03× | ||
| Q4 24 | — | 1.84× | ||
| Q3 24 | 3.86× | 1.57× | ||
| Q2 24 | 2.50× | 2.87× | ||
| Q1 24 | -1.78× | 5.67× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BXC
| Specialty Products | $525.5M | 70% |
| Structural Products | $223.4M | 30% |
RVTY
| Immunodiagnostics | $240.8M | 31% |
| Life Sciences | $191.4M | 25% |
| Reproductive Health | $149.3M | 19% |
| Segment Operating Income | $132.0M | 17% |
| Software | $62.3M | 8% |
